Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis con­sid­ers sell­ing its $5B+ oph­thal­mol­o­gy and res­pi­ra­to­ry units — re­port

As No­var­tis has been fo­cus­ing its core pipeline, and spin­ning off its gener­ics arm San­doz, the com­pa­ny may be look­ing to sell even more.

Ac­cord­ing to a re­port from Bloomberg to­day, the Swiss phar­ma is con­sid­er­ing the sale of some of its “non-core” as­sets to raise funds to in­vest in “cut­ting-edge med­i­cines,” peo­ple fa­mil­iar with the mat­ter said.

The re­port elab­o­rates that No­var­tis is in the ear­ly phas­es of “con­sid­er­ing op­tions” for its res­pi­ra­to­ry and oph­thal­mol­o­gy units, which wouldn’t close un­til af­ter San­doz spins out, with anony­mous sources telling the pub­li­ca­tion that pri­vate eq­ui­ty firms could spend up to $5 bil­lion on the oph­thal­mol­o­gy unit alone, ac­cord­ing to Bloomberg.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.